umbilical cord blood + C3a fragment

Umbilical cord blood + C3a fragment refers to a combination therapy in which hematopoietic progenitor cells from umbilical cord blood are primed ex vivo with complement fragment 3a (C3a) prior to transplantation. The rationale is that C3a priming enhances the homing and engraftment of CD34+ hematopoietic stem/progenitor cells by activating the CXCR4 receptor, thereby improving their migration toward stromal derived factor 1α (SDF-1α) gradients in the bone marrow. This approach has been investigated as a means to address delayed engraftment and graft rejection associated with standard umbilical cord blood transplantation, particularly for patients with advanced or high-risk hematological malignancies[1][2][6]. Clinical studies have shown that this method is safe, does not impair engraftment, and does not increase mortality or adverse events compared to historical controls; however, further preclinical optimization is needed before broader clinical adoption[1][2].

Other names

C3a-primed umbilical cord bloodC-3a-primed umbilical cord bloodC 3a-primed umbilical cord bloodumbilical cord blood primed with complement fragment 3a